Updated phase 2 data showed a 60% ORR and 86% CNS ORR with frontline silevertinib in non-classical EGFR-mutant NSCLC; FDA discussion supported a phase 3 trial in 2027.
|Videos|September 23, 2016
Metastatic Lung Cancer with Jared M. Weiss, MD: Case 2
Metastatic Lung Cancer with Jared M. Weiss, MD
Advertisement
Weiss case 2:
A 62 year-old neversmoker with stage IV adenocarcinoma
- Mutation testing showed an EGFR exon 19 mutation
- The patient was treated with erlotinib for 1 year; he developed diarrhea and rash which was successfully managed
- After 3 months, his disease showed progression on CT; he remained without symptoms.
- He subsequently developed cough and shortness of breath, correlated to progression of a centrally located lung lesion on his follow up CT scan
- Repeat biopsy and molecular testing of the central lesion showed EGFR T790M-positivity
- He was switched to osimertinib therapy and achieved a partial response
- The patient reported dramatic improvement in his well-being
Advertisement
Related to this article
FDA issues a not approvable letter for Novocure’s Optune Mya in NSCLC brain metastases, citing uncertain clinical benefit. No safety concerns were raised.
Imneskibart showed promising outcomes and tolerability in patients who had previously received immune checkpoint inhibition for either melanoma or lung adenocarcinoma.
In KEYNOTE-867, adding pembrolizumab to radiotherapy did not extend event-free survival in inoperable early-stage NSCLC and raised toxicity; the phase 3 trial was stopped for futility in 2024.
Advertisement
Advertisement
Trending on Targeted Onc
1
FDA Approves OncoMate MSI Dx For Pembrolizumab in MSI-H Tumors
2
Novocure’s Optune Mya Gets FDA Not Approvable Letter
3
Anbal-Cel Demonstrates Clinical Activity in Relapsed LBCL
4
In Phase 3, Ponatinib/Blinatumomab Improves EFS in Ph+ ALL
5